6 New Members Join the CATALIS Network
CATALIS is proud to welcome four new HSSIs, one new pharmaceutical company, and one new patient organization that have just joined its extensive Network of partners.
4 New HSSIs Join the CATALIS Network
CATALIS Quebec is proud to announce that the reach of its services now extends to 27 institutions across the province, with the integration of four (4) new health and social services institutions (HSSIs) into its Network of partners: The CISSS de la Côte-Nord, the CISSS Gaspésie, the CISSS de la Montérégie-Est, and the CISSS de la Montérégie-Ouest.
The Johnson & Johnson Pharmaceutical Company Joins the CATALIS Network
CATALIS is pleased to welcome the Johnson & Johnson Innovative Medicine Canada pharmaceutical company to its Network of partners. Johnson & Johnson focuses its efforts on complex diseases and develops the medicines of tomorrow in various fields, such as oncology, immunology, neuroscience, and rare diseases.
Johnson & Johnson joins the industry partners already engaged with our Network: Abbvie, Alexion, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences Canada Inc., GSK, Lilly Canada, Merck, Novartis, Novo Nordisk Canada Inc., Pfizer, Roche, Sanofi, Takeda, and Vertex.
“Johnson & Johnson is proud to collaborate with the CATALIS Network to drive clinical trials forward in the province. This is a win for patients, who will gain access to leading edge research; for clinicians and other researchers, who are helping accelerate the pace of discovery; and for the health and life sciences sectors, which will see growth of the discovery industry in support of the rapid commercialization of potentially life-changing innovations.”
– Ebele Ola, Vice President, Medical Affairs
The Canadian Hemophilia Society – Quebec Chapter Joins the CATALIS Network
CATALIS Quebec is pleased to welcome the Canadian Hemophilia Society – Quebec Chapter to its Network of partners!
The Canadian Hemophilia Society – Quebec Chapter is committed to improving the health and quality of life of people with inherited blood-clotting disorders by ensuring access to the best available treatments and well-equipped care centers.
Alongside more than thirty patient organizations and patient partners representing the voices of patients and caregivers within our Network, the CHSQ strengthens our shared commitment to accelerating medical innovation for the population of Quebec.
“Thanks to our partnership with CATALIS, we will be able to achieve our goal of providing patients with tools to learn about clinical trials and discuss them with their hematologist. We also believe that the CATALIS Network provides a collaborative space to discuss innovative treatments using a learning organization approach. We are proud and excited to join the CATALIS Network, a key partner in our mission to improve the quality of life for people with coagulation disorders.”
– Aline Ostrowski, Executive Director of the Canadian Hemophilia Society – Quebec Chapter
CATALIS would like to thank all members of its Network for their expertise and commitment to accelerating the development of innovative treatments. Together, we continue to improve the clinical research ecosystem for the well-being of patients in Quebec.
For more information about CATALIS and its services, please write to us at: info@catalisquebec.com.
